Search - tctmd.com

Displaying 301 - 320 of 407

Sort: Relevancy | Date

News Features

An Age/Old Dilemma? Pulling Senior Cardiologists From the Front During COVID-19

Todd Neale

April 14, 2020

News Opinion CV Team Dispatch

April 2020 News Roundup

L.A. McKeown

April 10, 2020

News Features

Cardiac Rehab During COVID-19: Telehealth, Unpaid Heroes Step Up to Help at Home

L.A. McKeown

April 10, 2020

News Daily News

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

Todd Neale

April 10, 2020

News Daily News

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

Michael O'Riordan

April 08, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Daily News

COVID-19 Drug Candidates May Raise Arrhythmia Risk

Caitlin E. Cox

April 03, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2020

Shelley Wood

April 01, 2020

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

L.A. McKeown

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News ACC 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

Michael O'Riordan

March 31, 2020

News Conference News ACC 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

Yael L. Maxwell

March 31, 2020

News Conference News ACC 2020

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

Caitlin E. Cox

March 31, 2020

Presentation ACC 2020

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presenter: Deepal L. Bhatt

March 30, 2020

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Advertisement

An Age/Old Dilemma? Pulling Senior Cardiologists From the Front During COVID-19

April 2020 News Roundup

Cardiac Rehab During COVID-19: Telehealth, Unpaid Heroes Step Up to Help at Home

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

COVID-19 Drug Candidates May Raise Arrhythmia Risk

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

TCTMD’s Top 10 Most Popular Stories for March 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content